Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar

BACKGROUND: Filgrastim and other granulocyte colony-stimulating factors are recommended to decrease febrile neutropenia (FN) incidence among patients with nonmyeloid cancers undergoing chemotherapy. Data comparing biosimilar filgrastim-sndz with reference filgrastim (filgrastim-ref) are limited outs...

Full description

Saved in:
Bibliographic Details
Published in:Clinicoecon Outcomes Res
Main Authors: Schwartzberg, Lee S, Lal, Lincy S, Balu, Sanjeev, Campbell, Kim, Brekke, Lee, Elliott, Caitlin, Korrer, Stephanie
Format: Artigo
Language:Inglês
Published: Dove Medical Press 2018
Subjects:
Original Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6126503/
https://ncbi.nlm.nih.gov/pubmed/30214262
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S168298
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items